reason report
result total revenu miss consensu
estim pro-forma ep beat
consensu miss estim reassuringli
eylea beat consensu estim us dupix kevzara
praluent previous disclos partner sanofi fell short
consensu prior estim total revenu
consensu estim sanofi collabor revenu
also came expect posit expens varianc result
better oper margin perform consensu model
although improv oper margin compar
prior period expens guidanc reduc slightli tax
rate guidanc improv modestli well
question magnitud recoveri us dupix sale
disclos headwind inventori draw-down
gross net adjust taken face valu compani
commentari could lead sale would
signific recoveri compar result better
perform dupix growth praluent sustain growth eylea
initi sale cemiplimab essenti regeneron stock
see sort recoveri second half
averag price-to-earnings p/ dcf
net debt total capit
price-to-earnings lt ep growth
compani inform leerink partner llc research
revenu mm dilut ep non-gaap
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
price target regeneron stock rate outperform regeneron
veteran biopharmaceut compani come initi base portfolio fast-
follow second entrant rapidli grow biopharmaceut market first product eylea
continu surpris investor taken grow market intraocular
vegf vascular endotheli growth factor antibodi treatment eylea contribut nearli
global sale trump categori pioneer roch lucenti well
cheaper altern bevacizumab remain posit eylea expect continu
grow lose market share emerg competitor
abicipar like view gain approv excit aspect compani
next wave innov antibodi notabl dupix await approv
first like multipl allerg diseas indic expect dupix
dupilumab gener revenu signific upsid
indic longer term regeneron wholli own antibodi could contribut
meaning revenu earn growth period current compani
invest mode result earn cash flow convers revenu lag peer
industri anticip cash flow true earn improv
period profit antibodi collabor sanofi begin accumul
sale line consensu number us sale eylea
consensu estim regeneron disclos
small inventori increas level normal week
rang howev benefit off-set higher govern channel rebat call
regeneron also disclos intern survey demonstr us eylea sale
wetamd dme compani plan increas commerci
invest diabet eye diseas sbla approv non-prolif diabet
retinopathi next year believ still signific growth ahead product
expect us eylea estim increas base result potenti
follow-though next year consensu forecast low mid-single-digit growth
product ex-u eylea sale consensu estim
estim result sanofi collabor product
previous disclos last friday sanofi varianc consensu estim
alreadi anticip market praluent sale dupix sale
significantli consensu estim forecast
last friday total collabor revenu regeneron partnership sanofi bayer
teva teva quarter consensu
estim reflect lower spend relat lower revenu reimburs
lower expens tax rate drove ep regeneron report total non-gaap
oper expens consensu estim
surpris balanc sg
lower consensu forecast expect expens
increas next quarter regeneron plan increas market presenc eylea
broader diabet eye diseas prepar dupix asthma launch begin plan
direct-to-consum advertis campaign dupix regeneron also report lower tax
rate compar consensu forecast combin two item help
deriv pro forma ep consensu
estim
guidanc updat forecast lower expens regeneron favor updat
element prior guidanc includ expens tax capit expenditur
regeneron lower non-gaap unreimburs guidanc
non-gaap sg guidanc
updat estim sg respect
regeneron also expect effect tax rate rang compar
prior total sanofi reimburs commerci relat expens expect
prior reduct regeneron intern expens
lower top-end rang sanofi commerci expens view
posit investor increasingli focus compani top-lin challeng less
dupix clinic regulatori event scatter next month
regeneron expect receiv regulatori approv applic origin atop
dermat adult indic outsid unit state us fda decis sbla
asthma adult/adolesc patient occur pdufa date octob
compani expect report phase data adolesc year age atop
dermat year regeneron would clarifi exact quarter note trial
primari studi complet date may studi complet date juli
would expect data give compani time file year-end toward year-end
also anticip data phase studi nasal polyp regeneron replac
conclud trial new pivot studi eosinophil esophag eoe chronic obstruct
pulmonari diseas copd well exploratori studi allergi
cemiplimab approv like octob pdufa one regeneron
import catalyst approv antibodi cemiplimab cscc
compani pdufa date octob revenu model base
anticip earlier approv compani omit usual re-stat pdufa date
top italic highlight portion earn press releas research suggest
first approv checkpoint antibodi new indic typic come ahead pdufa
date particularli true applic benefit breakthrough design
prioriti review case cemiplimab review length time file
approv initi approv tumor type date found approv
occur averag month pdufa therefor anticip approv
cemiplimab june juli includ initi sale compar consensu
also anticip earlier approv regeneron also appear signal
compani expect approv occur earlier date confirm us
commerci team readi launch product immedi avail channel
june regeneron present updat analysi pivot cscc studi focus
cemiplimab long-term activ durabl suggest may addit
data studi indic meet
i/o strategi gain clariti regeneron ultim goal becom
second approv front-lin monotherapi non-smal cell lung cancer nsclc
advanc asset multipl tumor type multipl combin regeneron
present first cemiplimab lung data june titl present yet
avail on-line manag indic small cohort patient advanc
non-smal cell lung cancer regeneron also provid updat develop
bispecif antibodi like drug still dose escal regeneron
disclos maximally-toler dose yet reach though asset wholly-own
regeneron develop timelin slow believ select pivot
dose meaning event regeneron also expect bispecif enter
clinic year compani disclos whole new class bispecif antibodi later
eylea extens track though eylea oldest product regeneron
compani multipl import updat first compani plan submit sbla
treatment npdr soon lead potenti approv also
potenti fda approv eylea dose interv could diminish
alleg differenti competitor brolucizumab set august regeneron
also plan submit sbla pre-fil syring version eylea product improv alreadi
util roch lucenti well-receiv market
conserv dupix sanofi collabor revenu pt even
though eylea longer rapid growth driver asset matur stabl cash gener
consensu estim mid-singl digit growth next year kept us forecast
unchang rais forecast ex-u sale regeneron share profit
given strong sequenti growth momentum
slower expect launch trajectori praluent kevzara lower sale forecast
substanti still optimist long term potenti
product despit disappoint miss dupix believ underli
demand intact headwind channel inventori patient assist program cost
one-off therefor slightli rais estim short-term sale growth
took conserv view peak sale long run materi updat
forecast collabor revenu sanofi decreas
base structur agreement chang lower revenu
forecast regeneron next year still consensu
ep forecast reduc period
base chang revenu earn forecast chang
relev peer compani multipl adjust target price reiter
outperform rate stock
price target regeneron base simpl averag three approach
believ reason basi valu stock today approach simpl price
earn multipl compar high growth larg molecul biopharmaceut compani price
sale multipl larg cap high growth compani discount cash flow dcf use
averag larg cap larg molecul therapeut compani nvo
earn multipl ep appli current ep estim
give valu use high growth revenu multipl similar compani
nvo consensu sale appli revenu
estim give valu lastli dcf valuat given wacc
termin cash flow growth rate give present valu averag
three method current price target upon complet analysi quarterli
result revisit price target present remain unchang
risk view outlook valuat regeneron includ major chang price
reimburs coverag label competit posit eylea compani main
product today risk includ commerci develop disappoint compani
next partner program launch dupix kevzara well continu weak
demand compani cholesterol treatment praluent subsequ releas
cardiovascular outcom data regeneron fail match cardiovascular outcom
demonstr rival product would advers affect
revenu outlook valuat lastli compani convert rel littl
revenu cash flow today histori return cash investor ultim
may undermin valu stock investor willing continu
sale
collabor
share count period dilut mm
guidanc
tax non-gaap pre-tax incom
sanofi reimburs regeneron
leerink partner research compani file zack factset consensu
leerink partner research compani file zack factset consensu
time event
phase result adolesc patient year
age
fda approv dose interv
fda approv use apheresi
asco data pivot cscc long-term initi
fda approv adult/adolesc patient
sbla submiss adolesc patient
year age
leerink partner research compani report present clinicaltri gov
copd co-morbid
initi phase ii studi adjunct
eu japan regulatori submiss
sbla submiss pre-fil syring
homozyg
copd atop
late stage pipelin program includ
late stage pipelin program exclud
praluent outcom
eylea dr w/o dme
nsclc basal cell
million
leerink partner research compani file
million
good sold
research develop
sell gener administr
collabor manufactur
 total revenu
sg total revenu
leerink partner research compani file
analysi stock price leerink partner target regeneron
method high growth larg cap growth biotech ep multipl
current larg cap larg molecul therapeut compani multipl
leerink partner forma ep estim
impli price ep
equiti
number period
method larg cap growth biopharma forward multipl enu
discount
larg cap high growth biopharma price/sal multipl nvo
leerink partner revenu forecast
impli ev revenu
share count
ev per share
expect net per share
net expect valu per share
equiti
number period
impli share price
present valu po adjust flow
pv termin valu
net
share count
averag method
leerink partner research compani file factset
